Quantitative risk-benefit analysis of alosetron in irritiable bowel syndrome: A patient-level meta-cohort analysis

Larry D. Lynd; Lindsey Colley; Mehdi Najafzedeh; Mark J. Sculpher; Andrew R. Willan; Reed F. Johnson; Semra Ozdemir

Quantitative risk-benefit analysis of alosetron in irritiable bowel syndrome: A patient-level meta-cohort analysis

Larry D. Lynd, Lindsey Colley, Mehdi Najafzedeh, Mark J. Sculpher, Andrew R. Willan, Reed F. Johnson, Semra Ozdemir

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	S183-S183
Number of pages	1
Journal	Pharmacoepidemiology and drug safety
Volume	16
Publication status	Published - Aug 2007

Cite this

@article{3e5d32918d184552a555f2469fae2734,

title = "Quantitative risk-benefit analysis of alosetron in irritiable bowel syndrome: A patient-level meta-cohort analysis",

author = "Lynd, {Larry D.} and Lindsey Colley and Mehdi Najafzedeh and Sculpher, {Mark J.} and Willan, {Andrew R.} and Johnson, {Reed F.} and Semra Ozdemir",

year = "2007",

month = aug,

language = "English",

volume = "16",

pages = "S183--S183",

journal = "Pharmacoepidemiology and drug safety",

issn = "1053-8569",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Quantitative risk-benefit analysis of alosetron in irritiable bowel syndrome: A patient-level meta-cohort analysis

AU - Lynd, Larry D.

AU - Colley, Lindsey

AU - Najafzedeh, Mehdi

AU - Sculpher, Mark J.

AU - Willan, Andrew R.

AU - Johnson, Reed F.

AU - Ozdemir, Semra

PY - 2007/8

Y1 - 2007/8

M3 - Article

SN - 1053-8569

VL - 16

SP - S183-S183

JO - Pharmacoepidemiology and drug safety

JF - Pharmacoepidemiology and drug safety

ER -